Despite global challenges, 2020 allowed us to step back and take a critical look at the needs of our sponsors and members ― not just in the moment, but with an eye toward a future we envision as filled with meaningful change, including in the area of specialty drugs.
In part 2 of our 2020 Drug Trend Report, we share our expertise in specialty drug management across both medical and pharmacy benefits. This supplement showcases our ability to keep specialty trend in the single digits, despite a challenging year.
- 2020 Commercial specialty trend, which was 6.1% for medical and Rx combined
- Features on biosimilars; cancer and oncology; and MS drugs
- A look at specialty accumulator rules